Zydus Lifesciences Board Approves Buyback of Equity Shares Up to INR 1100 Crore
Zydus Lifesciences Limited announced on May 19, 2026, that its Board of Directors considered and approved a significant proposal to buy back its own fully paid-up equity shares. The buyback will be executed at a price of INR 1,150 per share, representing an aggregate size not exceeding INR 1100,00,00,000.The Board approved the purchase of up to 95,65,217 fully paid-up equity shares, each having a face value of INR 1. This quantity represents up to 0.95% of the company's total paid-up equity share capital. The buyback price has been set at INR 1,150 per Equity Share, payable in cash.
The total proposed size for the buyback, capped at INR 1100,00,00,000, is calculated as 5.16% of the aggregate of the fully paid-up equity share capital and 3.84% of the free reserves, based on the latest audited standalone and consolidated financial statements as of March 31, 2026.
Buyback Mechanism and Timeline
The company plans to execute the buyback from all equity shareholders and beneficial owners, including promoters, on a proportionate basis through a tender offer route.
The Board also designated May 29, 2026, as the record date for determining the eligibility and names of the equity shareholders participating in the buyback. Furthermore, the company formed a Buyback Committee and delegated powers to it to handle all acts necessary for the execution of the buyback.
Pre-Buyback Shareholding Pattern
The pre-buyback shareholding pattern of Zydus Lifesciences Limited as of May 15, 2026, shows a total paid-up capital of 100,62,33,990 shares across various categories.
The detailed pre-buyback shareholding pattern is as follows:
| Shareholder Category | Number of shareholders | No. of equity shares held | % of shareholding |
|---|---|---|---|
| Promoter and promoter group | 12 | 75,46,25,314 | 74.995 |
| Mutual funds | 161 | 4,92,83,636 | 4.8978 |
| Alternative investment funds | 12 | 3,82,953 | 0.0381 |
| Foreign portfolio investor | 677 | 6,90,13,371 | 6.8586 |
| Financial institutions / banks | 7 | 5,39,581 | 0.0536 |
| Insurance companies | 30 | 6,15,76,172 | 6.1195 |
| Central/ State Governments | 3 | 16,504 | 0.0016 |
| Individuals (upto INR 2 lacs) | 4,14,170 | 4,88,14,256 | 4.8512 |
| Individuals (above INR 2 lacs) | 6 | 72,02,910 | 0.7158 |
| NBFCs registered with RBI | 4 | 2,246 | 0.0002 |
| Investor Education Protection Fund | 1 | 17,19,113 | 0.1708 |
| Trusts | 18 | 1,97,918 | 0.0197 |
| HUF | 4,909 | 15,05,713 | 0.1496 |
| NRIs (repat and non-repat) | 10,783 | 33,82,862 | 0.3362 |
| Bodies corporate/ clearing members | 1,028 | 59,71,790 | 0.5935 |
| LLP, foreign nationals | 119 | 3,11,814 | 0.031 |
| Unclaimed or Suspense or Escrow Account | 1 | 1,45,320 | 0.0144 |
| Others | 10 | 15,42,517 | 0.1533 |
| Total | 4,31,951 | 100,62,33,990 | 100 |
The details regarding the post-buyback shareholding pattern will be ascertained subsequently.
The buyback details include:
| Particulars | Details |
|---|---|
| Number of securities proposed for buyback | 95,65,217 |
| Percentage of existing paid-up capital | 0.95% |
| Buyback price | Rs. 1,150 per share |
ZYDUSLIFE Stock Price Movement
Today, Zydus Lifesciences Limited shares edged higher, gaining 2.56% on the board to settle near ₹1018.95. The stock saw robust trading throughout the session, with a total volume of 5.85 million shares transacted.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.